AstraZeneca declared availability of BYDUREON BCise for Type-2 Diabetes

AstraZeneca declared that BYDUREON BCise was now available in pharmacies across the U.S. An injectable suspension 2mg sanctioned by the U.S FDA for adults afflicted with Type-2 Diabetes whose blood sugar levels remained rampant despite one or more oral ant diabetic medicines in addition to diet and exercise.

BYDUREON BCise is an enhanced once-weekly, single-dose aautoinjector device designed to ensure patient convenience in a pre- filled device. Testified to lessen blood sugar levels including the possibility of shedding weight being administered in three steps- mix, unlock, inject.

Rod Wooten, Vice President, Cardiovascular and Metabolic Diseases, AstraZeneca, said: “We’re pleased that BYDUREON BCise, a new once-weekly treatment option in an easy-to-use device, is now available for adults with type 2 diabetes. This new formulation helps to provide consistent glycemic control, in addition to the powerful HbA1c reductions and added benefit of weight loss, now in a simply improved device.”

The two Clinical Trials witnessed average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds when used as monotherapy or as an add-on to metformin, a sulfonylurea, a thiazolidinedione, or any combination of two of these oral antidiabetic medicines at 28 weeks.

Diet and exercise has to be supplemented with BYDUREON and BYDUREON BCise to enhance glycemic control in adults with type-2 diabetes mellitus thereby not recommended for patients devoid of diet or exercise. The injectable suspension is subject to risks of thyroid C-cell Tumors and warnings for Acute Pancreatitis, Hypoglycemia, Acute kidney injury and impairment of Renal function.

Image Source: AstraZeneca